228 related articles for article (PubMed ID: 21154128)
1. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
Wang Y; Trepel JB; Neckers LM; Giaccone G
Curr Opin Investig Drugs; 2010 Dec; 11(12):1466-76. PubMed ID: 21154128
[TBL] [Abstract][Full Text] [Related]
2. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
Choi HK; Lee K
Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
[TBL] [Abstract][Full Text] [Related]
3. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
4. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
5. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
7. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
8. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
10. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
11. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
Tsutsumi S; Neckers L
Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Jhaveri K; Modi S
Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
[TBL] [Abstract][Full Text] [Related]
14. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
15. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
[TBL] [Abstract][Full Text] [Related]
16. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
17. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
19. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
[TBL] [Abstract][Full Text] [Related]
20. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
